Dr. Lamberts career spans high-profile academic institution such as Cambridge University and the Dana-Farber Cancer Institute, Harvard Medical School, from where he joined ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics.
Dr. Lambert covered a variety of roles at ImmunoGen, eventually to serve as Chief Scientific Officer Executive Vice President from 2008 until 2015. During Dr Lambert’s tenure in leadership roles at ImmunoGen, scientists at the Company invented the ADC technology that ultimately resulted in the Genentech/Roche drug, KADCYLA® (approved in 2013 for treating HER2+ breast cancer) as well as numerous other ADCs taken into clinical development. One of these ADCs is ImmunoGen’s ADC ELAHERETM that recently received accelerated approval from FDA (November 14, 2022) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer.
Since 2018 to date, Dr Lambert consults with and/or advises a number of Biopharma and Pharma companies, and some VC firms, on ADC technologies and ADC development.
Dr. Lambert is the author/co-author of over 125 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2018, he was appointed to an Honorary Professorship at Queen’s University Belfast, Northern Ireland, UK.